London-based Cryogenx has raised €1.9 million as part of Seed funding round to accelerate the development of its portable cooling technology to combat heat strokes.
The UK Innovation & Science Seed Fund (UKI2S), managed by Future Planet Capital, has invested €495k in Cryogenx as part of the funding round.
Founder and CEO of Cryogenx, Matt Anderson, added: “Heatstroke isn’t just an isolated risk; it’s a rising global threat – and existing solutions simply aren’t practical enough to meet the challenge. We’ve designed CGX1 as a defibrillator for heatstroke, providing frontline responders and military personnel the ability to treat heat-related illness effectively, wherever it strikes.
“The backing from UKI2S is pivotal – it not only validates our mission but gives us the resources to accelerate regulatory clearance, scale manufacturing, and get this lifesaving technology into the hands of those who need it most.“
Founded in 2020, Cryogenx develops portable on-demand cooling devices designed to rapidly treat heatstroke and heat-related illnesses in-the-field. Their flagship product, CGX1, eliminates the need for cold-chain logistics and can be deployed in remote, industrial, military, and emergency response settings.
The company is targeting global markets across defence, industry, and climate adaptation sectors.
The CGX1, is designed to deliver rapid, life-saving treatment for heatstroke and heat-related illness- all without the need for ice, refrigeration, or complex cold-chain logistics. Described as a “defibrillator for heat”, the lightweight device can be deployed in minutes, making it a potential game-changer for military, industrial, and emergency response applications where high temperatures put lives and operations at risk.
“This is exactly the kind of innovation we target in our defence and security investments,” said Alex Leigh, Investment Director at UKI2S, managed by Future Planet Capital. “Cryogenx is addressing a critical, global challenge with a solution that has the potential to transform how we prevent and manage heat injuries across sectors. We’re proud to support them as they scale their impact and set a new benchmark for operational safety and resilience.”
Cryogenx is focused on dual-use applications, with strong relevance for defence customers like the UK Ministry of Defence (MOD) and the US Department of Defense (DoD), where Cryogenx says exertional heat illness is a persistent and costly issue. The company is also eyeing rapid expansion into civilian sectors, including energy, construction, mining, emergency services, and sports.
The funding will be used to drive FDA clearance, scale up manufacturing, and expand international sales. Cryogenx is also developing lighter, modular versions of its technology and planning a subscription-based model to build long-term revenue.
By 2030, 700 million people are projected to be exposed to extreme heat, with the resulting productivity losses expected to top €2 trillion annually. Core body temperatures exceeding 39°C can be fatal, and even sub-lethal heat stress sharply reduces physical and cognitive performance – according to data provided by Cryogenx.
Four environmental factors – temperature, humidity, radiant heat, and wind speed – combine to push workers beyond safe limits, according to research from the National Institute for Occupational Safety and Health (NIOSH). Once body temperatures rise above 38°C, heat exhaustion sets in; at 40.6°C, the risk of organ failure and death from heatstroke increases dramatically.
Cryogenx’s innovation looks to tackle this head-on, providing a scalable, portable solution at a time when climate-driven heat stress is emerging as one of the most urgent global health and economic challenges.
Read the orginal article: https://www.eu-startups.com/2025/07/british-startup-cryogenx-raises-e1-9-million-to-tackle-deadly-heat-stress-in-military-and-industry/
